To validate the efficacy of GALNT14-rs62139523 and DNMBP-rs10786578 genotypes as potential biomarkers for predicting the therapeutic response to 5-FU-based adjuvant chemotherapy following curative surgical resection in intermediate-stage CRC patients, an additional cohort comprising 195 patients was retrospectively enrolled as the validation cohort. Here, DNMBP is linked to colorectal carcinoma.